Setmelanotide
An FDA-approved MC4R agonist for rare monogenic obesity (POMC/PCSK1/LEPR deficiency, Bardet-Biedl syndrome) and — as of March 2026 — acquired hypothalamic obesity in patients aged 4 and older.
What is Setmelanotide?
Setmelanotide is a cyclic peptide that activates the melanocortin-4 receptor (MC4R), a key regulator of appetite and energy balance. It is FDA-approved for chronic weight management in patients with specific rare genetic obesity conditions (POMC, PCSK1, or LEPR deficiency), Bardet-Biedl syndrome (BBS), and — as of March 2026 — acquired hypothalamic obesity in adults and pediatric patients aged 4 and older. It represents one of the first precision medicine approaches to obesity treatment, with its most recent approval making it the first and only approved therapy for acquired hypothalamic obesity.
What Setmelanotide Is Investigated For
Setmelanotide is investigated and FDA-approved for rare MC4R-pathway obesity — POMC, PCSK1, and LEPR deficiency, plus Bardet-Biedl syndrome — and, as of March 19, 2026, for acquired hypothalamic obesity in patients aged 4 and older. The strongest evidence is in exactly these populations, where 52-week trials produced mean weight loss of about 23% in POMC/PCSK1 deficiency and about 10% in LEPR deficiency (single-arm trials, not placebo-corrected), and a mean BMI reduction of about 8% in BBS. That same randomized trial also enrolled patients with Alström syndrome, in whom the results were inconclusive — only three per arm — and Alström syndrome never received an approved indication. The March 2026 acquired-HO approval was supported by the pivotal Phase 3 TRANSCEND trial (n=142): setmelanotide produced a −15.8% BMI reduction vs. a +2.6% increase on placebo at 52 weeks — an 18.4% placebo-adjusted effect (the 120-patient primary cohort, published in the New England Journal of Medicine in July 2026, showed −16.5% versus +3.3%), in a disease (hypothalamic injury-driven obesity, ~10,000 US patients) with no previously approved therapy. The biology is precision-medicine clean in each approved population: the leptin-melanocortin satiety pathway is disrupted upstream (monogenic) or at the hypothalamic site (acquired HO), and setmelanotide restores the missing MC4R signal. The honest caveats are narrow but important. The drug is not effective for general polygenic obesity, and the side-effect profile (skin darkening in about two-thirds of patients, labeled depression and suicidal ideation warnings, sexual adverse events) is not justified outside approved indications. Long-term cardiovascular, neuropsychiatric, and pediatric-development safety beyond trial follow-up remains under active surveillance, and combination regimens with GLP-1 agonists are unstudied.
History & Discovery
Setmelanotide emerged from research at Ipsen and was acquired and developed by Rhythm Pharmaceuticals, a Boston biotech founded specifically to advance precision treatments for rare melanocortin-pathway obesity disorders. The molecule's design — a cyclic octapeptide with high MC4R selectivity relative to first-generation tool compounds like Melanotan II — was driven by decades of academic genetics work establishing that loss-of-function mutations in POMC, PCSK1, LEPR, and MC4R itself produce severe early-onset obesity by disrupting the leptin-melanocortin satiety pathway in the hypothalamus. The therapeutic hypothesis was straightforward: in patients whose upstream signaling is broken but whose downstream MC4R is intact, providing an exogenous MC4R agonist could restore the missing 'fullness' signal. Rhythm advanced setmelanotide through Phase 1 and 2 trials in MC4R-pathway obesity in the mid-2010s, with proof-of-concept results in POMC deficiency (two patients, NEJM 2016) and LEPR deficiency (three patients, Nature Medicine 2018) demonstrating dramatic weight loss in patients who had been unable to lose weight through any conventional intervention. Pivotal Phase 3 single-arm trials in POMC, PCSK1, and LEPR deficiency formed the basis for the November 2020 FDA approval of Imcivree — a notable approval because the indicated population is vanishingly small (low thousands of patients globally) and because the trials were single-arm and open-label, with only a short blinded placebo-withdrawal period — a design suited to the rarity of the disease. In June 2022, FDA expanded the indication to include Bardet-Biedl syndrome (BBS) following a randomized Phase 3 trial showing significant weight reduction. In December 2024 the FDA extended the BBS and POMC/PCSK1/LEPR indications down to age 2, based on the 12-patient VENTURE trial. On March 19, 2026, the FDA approved setmelanotide for a fundamentally different population: acquired hypothalamic obesity in adults and pediatric patients aged 4 and older. Unlike the prior monogenic indications, acquired HO is not a germline genetic disease — it results from injury (surgery, radiation, tumor) to the hypothalamic appetite-regulation centers, most often after childhood craniopharyngioma resection. Rhythm estimates approximately 10,000 US patients with acquired HO. The approval rested on the pivotal Phase 3 TRANSCEND trial (n=142), which showed a −15.8% BMI reduction on setmelanotide versus +2.6% on placebo at 52 weeks — an 18.4% placebo-adjusted effect. This made Imcivree the first and only approved therapy for acquired hypothalamic obesity. The 120-patient primary cohort was published in the New England Journal of Medicine in July 2026 (BMI −16.5% on setmelanotide versus +3.3% on placebo). In Europe, a positive CHMP opinion on 26 March 2026 was followed by European Commission authorization on 1 May 2026, the UK MHRA added the indication on 11 August 2026, and Japan approved it on 24 August 2026. The acquired-HO approval has also opened an adjacent frontier: MC4R agonism is now being explored in other syndromic forms of hypothalamic obesity, including ROHHAD syndrome (rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation), where a 2026 single-patient case report described off-label setmelanotide producing 28% weight loss in a boy with ROHHAD, followed by 10% regain within 3 months after insurance stopped covering it. Not every expansion has worked: in March 2026 the Phase 3 EMANATE trial in people carrying a single (heterozygous) variant in POMC/PCSK1, LEPR, SRC1, or SH2B1 missed its primary endpoint in all four substudies. Imcivree is one of the clearer examples of mechanism-targeted obesity pharmacology in the modern era, now spanning both genetic and acquired disruption of the same leptin-melanocortin pathway.
How It Works
In certain rare genetic conditions, or after injury to the hypothalamus, the brain's appetite-control pathway is broken. Setmelanotide restores the missing signal by directly activating the MC4 receptor, which tells the brain 'you're full' — something these patients' bodies cannot do on their own.
Setmelanotide is a cyclic octapeptide that selectively agonizes MC4R in the hypothalamic paraventricular nucleus, restoring the leptin-POMC-MC4R signaling cascade that is disrupted in POMC, PCSK1, or LEPR deficiency, impaired in BBS, and damaged by hypothalamic injury in acquired hypothalamic obesity. MC4R activation reduces food intake and increases energy expenditure; in a 72-hour study in people with common obesity, it raised resting energy expenditure by about 6% (111 kcal a day). Setmelanotide has about 20-fold less activity at MC1R and MC3R than at MC4R. The skin hyperpigmentation side effect results from cross-reactivity with MC1R on melanocytes.
Evidence Snapshot
Human Clinical Evidence
Strong for approved indications. Single-arm Phase 3 trials showed at least 10% weight loss at 1 year in 8 of 10 POMC and 5 of 11 LEPR patients. The randomized Phase 3 TRANSCEND trial in acquired hypothalamic obesity (NEJM 2026) showed a 19.8-percentage-point difference in BMI change versus placebo in its primary cohort — that is, −16.5% on setmelanotide against +3.3% on placebo, not a 19.8-unit fall in BMI. The negative Phase 3 EMANATE trial in carriers of a single variant shows where the drug stops working.
Animal / Preclinical
Extensive, and unusually predictive of the clinical result. The decisive preclinical study was in diet-induced obese non-human primates, where the setmelanotide precursor BIM-22493/RM-493 produced a transient 35% fall in food intake but persistent 13.5% weight loss over 8 weeks with no rise in blood pressure or heart rate — while LY2112688, an earlier MC4R agonist already known to raise blood pressure in humans, did exactly that in the same model while barely reducing intake. That dissociation is the reason setmelanotide was developed at all, and it established that distinct melanocortin peptides can have widely different efficacy and side-effect profiles despite sharing a receptor. Nonclinical safety is also reassuring: setmelanotide was not carcinogenic in Tg.rasH2 mice at up to 10 mg/kg/day over 26 weeks, was neither mutagenic nor clastogenic, and produced no fertility effects in rats at 9 to 11 times the maximum recommended human dose.
Mechanistic Rationale
Very strong. The leptin-melanocortin pathway is one of the best-understood appetite-regulation systems in biology, and setmelanotide is a rare case of a drug slotting into a precisely known break in it. Cryo-EM structures of the setmelanotide-MC4R-Gq complex have since resolved the binding mode directly, and the downstream Gq/11 signaling in paraventricular-nucleus neurons is the step that produces appetite suppression. The acquired hypothalamic obesity indication extends the same logic to a non-genetic lesion: because these patients respond to an MC4R agonist, their MC4R-dependent machinery must still be intact, which has led some authors to reframe acquired hypothalamic obesity as an alpha-MSH deficiency state rather than a generic appetite disorder.
Research Gaps & Open Questions
What the current literature has not yet settled about Setmelanotide:
- 01Heterozygous variant carriers — the Phase 3 EMANATE trial found no significant BMI benefit over placebo at 52 weeks in people with one copy of a POMC/PCSK1, LEPR, SRC1, or SH2B1 variant (placebo-adjusted changes of −1.7% to −4.3%). Part of that failure now has a genetic explanation: a 2026 human-genetics study found no association between pathogenic NCOA1 variants (encoding SRC-1) and obesity or BMI, challenging the premise on which SRC1 carriers were enrolled. Rhythm plans to study POMC and SRC1 further with next-generation agonists, so whether any subgroup benefits remains open.
- 02Hormonal effects beyond weight — a 58-patient BBS cohort saw rises in reproductive hormones and IGF-1 and a fall in TSH within 6 months, partly independent of weight loss; the long-term clinical meaning is unknown.
- 03Adrenal and sodium safety in acquired hypothalamic obesity — serious acute adrenal insufficiency occurred in 5% of treated patients versus none on placebo, and serious adverse events overall were 28% versus 8% in the NEJM cohort. Why this happens, and which patients are most at risk, is not yet defined.
- 04Polygenic obesity efficacy — setmelanotide has been studied almost exclusively in monogenic and BBS populations; whether MC4R agonism produces meaningful weight loss in the much larger common-obesity population is unresolved, with mixed signals from earlier exploratory studies.
- 05Long-term cardiovascular and metabolic outcomes — the acute questions are now answered: a 72-hour crossover study found no adverse effect on heart rate or blood pressure, a dedicated 77-volunteer thorough-QT study established that setmelanotide does not meaningfully prolong the QT interval even at 2.3 times the maximum recommended dose, and the label reports numeric blood-pressure improvements alongside weight loss. What remains unmeasured is hard cardiovascular outcomes over years of continuous use.
- 06Depression and suicidality signal — the mechanism behind the labeled neuropsychiatric warning is not fully characterized, and predictors of which patients are at higher risk are not defined.
- 07Combination regimens — setmelanotide plus GLP-1 receptor agonists or other weight-loss agents has not been evaluated in adequately powered trials; mechanistic complementarity is plausible but unproven.
- 08Pediatric long-term safety — approval down to age 2 (monogenic) and age 4 (acquired HO) was supported by trial data with limited follow-up; long-term effects on growth, puberty, bone development, and neurodevelopment require ongoing surveillance.
- 09Real-world acquired-HO response — the TRANSCEND trial population had a defined hypothalamic-injury phenotype and a mean baseline BMI of 36 kg/m² across all 142 participants (range 21 to 70), which is class-2 obesity rather than the extreme phenotype sometimes assumed — though the adult subgroup averaged 41.2; how the effect translates across milder phenotypes, different injury etiologies (tumor vs. radiation vs. surgical), and longer time horizons is still accruing.
Forms & Administration
Once-daily subcutaneous injection at the start of the day, drawn from a 10 mg/mL multiple-dose vial with a 1-mL syringe and a 28- or 29-gauge needle. The starting dose depends on indication and age: 0.5 mg for acquired hypothalamic obesity at any age from 4 up; 2 mg for ages 12 and older with BBS or POMC/PCSK1/LEPR deficiency; 1 mg for ages 6 to 11; and 0.5 mg for ages 2 to 5. Doses are raised in 2-week steps toward 3 mg daily maintenance for ages 6 and older. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
For BBS and POMC/PCSK1/LEPR deficiency, the FDA-labeled starting dose for adults and children 12 and older is 2 mg once daily for 2 weeks, then 3 mg once daily as maintenance if tolerated. For acquired hypothalamic obesity, every age group (4 and older) starts lower, at 0.5 mg once daily for 2 weeks, with stepwise increases. Pediatric dosing is weight- and age-stratified: children aged 6 to 11 with BBS or POMC/PCSK1/LEPR deficiency start at 1 mg daily, step up to 2 mg, then to 3 mg maintenance if tolerated. Ages 2 to 5 (added December 2024) start at 0.5 mg, with a weight-based maintenance dose of up to 2 mg at 40 kg or more. Severe kidney impairment calls for a lower maintenance dose — 1.5 mg from age 12, 1 mg from 6 to under 12, and 1 mg from 2 to under 6 at 20 kg or more, with use not recommended under 20 kg — while mild and moderate impairment need no change; exposure rises 86% to 96% in severe impairment, and about 39% of a dose is excreted unchanged in urine. The drug is not recommended in end-stage kidney disease. Maximum daily dose across age groups is 3 mg. If a dose is missed, the label says simply to resume the once-daily regimen at the next scheduled dose rather than doubling up.
Frequency
Once daily subcutaneous injection at the beginning of the day, without regard to meals. The product is a 10 mg/mL solution in a 1-mL multiple-dose vial, drawn up with a 1-mL syringe and a 28- or 29-gauge needle; an opened vial is discarded after 30 days. Each vial contains 10 mg of benzyl alcohol and 5 mg of phenol as preservatives — relevant because benzyl alcohol is the ingredient behind neonatal gasping syndrome, though the approved age floor of 2 years keeps that population out of scope, and the label notes that fetal exposure is unlikely because a pregnant woman metabolises benzyl alcohol rapidly.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Setmelanotide is a chronic, open-ended therapy for the conditions it is approved to treat — there is no 'cycle' in the wellness-protocol sense. Treatment continuation depends on demonstrated weight-loss response and ongoing tolerability; the US label sets no fixed checkpoint. Stopping leads to weight regain because the underlying pathway defect, genetic or acquired, persists — in the POMC and LEPR trials, patients gained an average of 5.5 kg and 5.0 kg during 4 weeks on placebo.
Protocol Notes
Subcutaneous injection rotates between abdomen, thigh, and upper arm to minimize local site reactions. Skin hyperpigmentation is a near-universal pharmacological effect (not a side effect in the conventional sense) due to MC1R cross-activation: skin, lips, gums, hair, and existing nevi can darken, often noticeably within weeks. Patients should have a full-body skin examination before starting and periodically during treatment, watching for darkening of existing moles and any new moles. Spontaneous penile erections in males and sexual adverse events in both sexes — driven by central melanocortin activity overlapping with the bremelanotide arousal pathway — are reported and patients should be counseled. Depression, suicidal ideation, and suicide attempts have been reported in clinical trials and are a labeled warning; mood should be monitored, and the label advises considering discontinuation if suicidal thoughts or behaviors, or clinically significant or persistent depression, occur; people with a history of depression may be at higher risk of recurrence. Imcivree is a specialty medication. Eligibility rests on a qualifying diagnosis: a clinical diagnosis of acquired hypothalamic obesity or BBS, or genetic testing showing POMC, PCSK1, or LEPR variants. In acquired hypothalamic obesity the label adds two monitoring steps: watch for acute adrenal insufficiency in patients with secondary adrenal insufficiency (serious events in 5% on drug versus none on placebo), and check sodium in patients with central diabetes insipidus, adjusting their diabetes insipidus medication as needed.
Imcivree is FDA-approved only to reduce excess body weight in patients aged 4 and older with acquired hypothalamic obesity, and in patients aged 2 and older with Bardet-Biedl syndrome or with POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. Use for general (polygenic) obesity is not approved, has not been adequately studied, and should not be expected to produce the responses seen in MC4R-pathway disease.
Timeline of Effects
Onset
Subcutaneous setmelanotide reaches peak plasma concentration in approximately 8 hours; reductions in self-reported hunger are a consistent finding but their onset is not well characterized — the pivotal trials reported weekly-averaged hunger scores at 52 weeks rather than early timepoints, so the widely repeated claim that hunger falls within the first week has no published source behind it. Skin darkening is near-universal: the US label reports hyperpigmentation disorders in 67% of treated patients versus 0% on placebo during the 14-week placebo-controlled Bardet-Biedl period, and describes generalized or focal increases in skin pigmentation in the majority of treated patients. No published source gives a reliable time-to-onset. Measurable weight loss in eligible patients begins within the first month, with the bulk of the response accruing over months 3–12.
Peak Effect
In Phase 3 trials, peak weight reduction in POMC and LEPR deficiency populations was observed at approximately 12 months, with mean weight loss of about 23% in POMC/PCSK1 deficiency and about 10% in LEPR deficiency — single-arm trials, so not placebo-corrected. In BBS, mean BMI fell about 8% after 52 weeks. In acquired hypothalamic obesity, BMI fell 15.8% on drug versus a 2.6% rise on placebo at 52 weeks. Continued therapy beyond 12 months largely maintains rather than further increases weight loss.
After Discontinuation
Plasma half-life is approximately 11 hours, but the relevant clinical timeline is pathway-related rather than pharmacokinetic. Discontinuation removes the exogenous MC4R signal in patients whose endogenous signaling is genetically broken; weight regain begins within weeks of stopping. In the POMC and LEPR trials, a 4-week placebo withdrawal led to average gains of 5.5 kg and 5.0 kg, and weight fell again when treatment resumed; in a 2026 case report, a boy with ROHHAD regained 10% of his body weight within 3 months of stopping. The label describes the skin darkening as reversible after stopping, without giving a timeframe.
Common Questions
Is there a weekly or oral version of setmelanotide?
No weekly or oral version is approved. Rhythm completed a Phase 3 trial comparing weekly and daily setmelanotide in 2023, but no weekly product has been approved. Its oral MC4R agonist, bivamelagon, reduced BMI by 9.3% at the highest dose versus a 2.2% rise on placebo over 14 weeks in a small Phase 2 trial in acquired hypothalamic obesity, and Rhythm plans to start a pivotal Phase 3 trial by the end of 2026.
Are there special safety issues when setmelanotide is used for hypothalamic obesity?
Yes. Many people with acquired hypothalamic obesity also have pituitary hormone deficiencies. In TRANSCEND, serious acute adrenal insufficiency occurred in 5% of treated patients versus none on placebo, and among those with central diabetes insipidus, low sodium occurred in 6% versus 2%. The label calls for watching for adrenal crisis and checking sodium, alongside the standard warnings on mood, sexual side effects, allergic reactions, and moles.
Can anyone use setmelanotide for weight loss?
No. It is only FDA-approved for patients with (a) confirmed genetic mutations in POMC, PCSK1, or LEPR genes, (b) Bardet-Biedl syndrome, or (c) acquired hypothalamic obesity (added March 2026). Genetic testing (for POMC, PCSK1, or LEPR deficiency) or a clinical diagnosis (for BBS or acquired hypothalamic obesity) is required before prescribing. It is not approved for general polygenic obesity.
What is acquired hypothalamic obesity, and what did the TRANSCEND trial show?
Acquired hypothalamic obesity is severe, unrelenting weight gain following injury to the hypothalamus — typically after surgery, radiation, or tumor (most commonly craniopharyngioma) affecting the appetite-regulation centers. Rhythm estimates about 10,000 people in the US live with this condition. The pivotal Phase 3 TRANSCEND trial enrolled 142 patients and showed a −15.8% BMI reduction on setmelanotide vs. +2.6% on placebo at 52 weeks — an 18.4% placebo-adjusted effect. FDA approval for this indication came on March 19, 2026, making setmelanotide the first and only approved therapy for acquired hypothalamic obesity. About 61% of treated patients lost at least 10% of their BMI, versus about 5% on placebo. The 120-patient primary cohort was published in the New England Journal of Medicine in July 2026, and the European Commission (May 2026) and the UK MHRA (August 2026) have since authorized it for ages 4 and older, and Japan approved it in August 2026.
How is setmelanotide different from GLP-1 drugs like semaglutide or tirzepatide?
They are mechanistically and clinically distinct, not interchangeable. GLP-1 (and dual GIP/GLP-1) agonists act primarily on incretin pathways — slowing gastric emptying, improving insulin secretion, and producing satiety through a separate brainstem-and-hypothalamus signaling route — and they work in unselected (polygenic) obesity, which is the vast majority of patients. Setmelanotide acts downstream in the leptin-melanocortin pathway by directly agonizing MC4R, and it only produces large weight loss in patients whose upstream signaling is genetically broken (POMC/PCSK1/LEPR deficiency, BBS) or whose hypothalamus has been injured (acquired HO). GLP-1s have a far broader label and a much larger evidence base in common obesity; setmelanotide is a precision-medicine drug for narrow indications. The two have not been adequately studied in combination.
How quickly should weight loss appear, and when is treatment discontinued for non-response?
Hunger reduction is the earliest reported effect, though no published trial measured how quickly it begins — the pivotal studies reported hunger only as 52-week averages. Measurable weight loss begins within the first month, but the current US label sets no fixed response checkpoint, so whether to continue is a clinician's judgment. In the pivotal POMC and LEPR trials, only patients who had lost at least 5 kg (or 5% if they weighed under 100 kg) after 12 weeks moved on to the next phase. Responders see most of their weight loss accrue over months 3–12, with the response plateauing and being maintained thereafter as long as therapy continues. Stopping the drug in a responder typically leads to weight regain within months, because the underlying pathway defect persists.
Does a variant of uncertain significance (VUS) disqualify you?
No — and this is one of the most consequential misreadings of the label. The indication explicitly covers POMC, PCSK1, or LEPR variants interpreted as pathogenic, likely pathogenic, or of uncertain significance. Only variants classed as benign or likely benign are excluded. Because a large share of rare variants come back as VUS, reading a VUS result as a negative result wrongly rules people out of the one therapy targeted at their biology. There is also no FDA-approved companion test for these genes, so which laboratory does the sequencing and how it classifies variants genuinely affects eligibility. A published case of a heterozygous PCSK1 N221D carrier who lost 11.8% of body weight in three months shows the edges of the label are less tidy than the EMANATE result alone suggests.
Does setmelanotide cause cancer, liver damage, or affect fertility?
The available answers are reassuring on all three. Setmelanotide was not carcinogenic in Tg.rasH2 mice at up to 10 mg/kg/day over 26 weeks, and was neither mutagenic nor clastogenic in the standard genotoxicity battery. No fertility effects were seen in male rats at 9 times, or female rats at 11 times, the maximum recommended human dose. The NIDDK LiverTox monograph records no aminotransferase or bilirubin elevations and no cases of clinically apparent liver injury. A dedicated 77-volunteer study also found no clinically relevant QT prolongation even at 2.3 times the maximum dose. None of this covers decades of exposure beginning in early childhood, which is what long-term surveillance is for.
How often does a patient need skin checks?
The US label calls for a full-body skin examination before starting and periodically during treatment, watching for darkening of existing moles and any new ones, but it does not set an interval. Published practice fills the gap: a 2026 dermatology case report notes that exact screening guidelines have not been defined and recommends baseline and then annual examinations during treatment. The concern is not the pigmentation itself, which is an expected MC1R effect, but the need to be able to tell a benign drug-induced change from something that warrants biopsy — which is much easier with a documented baseline.
How do patients actually get access to setmelanotide?
In the US, prescribing requires (a) documented genetic testing confirming POMC, PCSK1, or LEPR deficiency, (b) clinical diagnosis of Bardet-Biedl syndrome, or (c) documented acquired hypothalamic injury — payers will not cover the drug without one of these. Most prescribing happens through specialty obesity, endocrinology, or pediatric metabolic-disease centers, and Rhythm operates a patient-support program that handles benefits investigation, prior authorization, and financial assistance for eligible patients.
Who Setmelanotide Is NOT For
- •Use in obesity that is not due to acquired hypothalamic obesity, BBS, or POMC, PCSK1, or LEPR deficiency (including general polygenic obesity and other genetic syndromes, where the label says it would not be expected to work) — efficacy in polygenic obesity is not established and the safety profile (depression risk, hyperpigmentation) is not justified by benefit in unselected populations.
- •Pregnancy and breastfeeding — the US label says to stop setmelanotide when pregnancy is recognized unless the benefits outweigh the risks, because weight loss during pregnancy may harm the fetus, and use while breastfeeding is not recommended.
- •Active or history of suicidal ideation or major depression — relative contraindication; very careful monitoring is required given the labeled warning for suicidal ideation and depression.
- •History of melanoma or significant atypical nevi — relative contraindication given the MC1R cross-activation and pigmentary changes; baseline and ongoing dermatologic surveillance is required.
- •Children under 2, or under 4 for acquired hypothalamic obesity — safety and effectiveness not established.
- •Kidney and liver disease — not recommended in end-stage kidney disease, or in acquired hypothalamic obesity with severe kidney impairment; other patients with severe kidney impairment need a lower dose. The effect of liver impairment on drug levels is unknown.
- •Prior serious hypersensitivity to setmelanotide or any ingredient, including anaphylaxis — the only formal contraindication on the US label; the other items here are cautions.
- •Acquired hypothalamic obesity with secondary adrenal insufficiency or central diabetes insipidus — not a contraindication, but the label calls for monitoring for acute adrenal insufficiency and for low or high sodium, adjusting diabetes insipidus medication as needed.
Drug & Supplement Interactions
Setmelanotide is metabolized through proteolytic peptidase pathways rather than cytochrome P450, so classical CYP-mediated drug interactions are minimal. Laboratory testing suggests a low potential for drug interactions through CYP enzymes, transporters, or protein binding, but no clinical drug-interaction studies have been done. The most relevant interaction concerns are pharmacodynamic rather than pharmacokinetic. Co-administration with other agents that modulate mood — SSRIs, SNRIs, mood stabilizers — does not have a documented PK interaction but warrants additional monitoring given the labeled depression and suicidal ideation warning. Co-administration with other weight-loss agents (semaglutide, tirzepatide, phentermine) has not been studied and is not part of any approved regimen; combining is off-label and not supported by data. In acquired hypothalamic obesity with central diabetes insipidus, doses of diabetes insipidus medication may need adjusting, guided by sodium monitoring. Two real clinical datapoints have now been published. In two paediatric kidney-transplant recipients with Bardet-Biedl syndrome treated with setmelanotide, ciclosporin trough concentrations remained stable and graft function was unaffected, with hyperpigmentation the only treatment-related adverse effect — the first direct observation involving a narrow-therapeutic-index immunosuppressant. Separately, a patient with Bardet-Biedl syndrome who had taken liraglutide with modest effect was switched to setmelanotide after stopping it and lost 10.5% of body weight over 12 months with improved transaminases and albuminuria; that is sequential use, not combination, and remains the only published datapoint on the two drug classes in one patient. Severe renal impairment raises setmelanotide exposure by 86% to 96%, which matters when it is co-prescribed with nephrotoxic agents. For patients receiving therapies with skin or pigmentary effects (PUVA, hydroxychloroquine, certain chemotherapeutics), the additive cosmetic effect of setmelanotide-induced hyperpigmentation should be discussed before initiation. As with any chronic injectable specialty therapy, patients should disclose all prescription, OTC, and supplement use to their prescriber.
Safety Profile
Common Side Effects
Cautions
- • Only for acquired hypothalamic obesity, BBS, or genetically confirmed POMC/PCSK1/LEPR deficiency
- • Acute adrenal insufficiency and sodium imbalance in acquired hypothalamic obesity (monitor)
- • Serious allergic reactions including anaphylaxis
- • New or darkening moles (periodic skin exams)
- • Risk of depression and suicidal ideation
- • Skin darkening is expected
- • Sexual adverse effects common
What We Don't Know
Long-term effects of chronic MC4R activation are still being studied, and the pooled safety picture is only now being quantified: a 2026 systematic review and meta-analysis of seven trials (n=185) put injection-site reactions at 96%, skin hyperpigmentation at 62%, nausea at 36%, vomiting at 26%, and diarrhoea at 21%, with a companion disproportionality analysis of 228 FAERS reports flagging hyperpigmentation, injection-site reactions, nausea, melanocytic naevi, and freckling as the principal signals. Two areas are better settled than they are often assumed to be: at 2.3 times the maximum recommended dose setmelanotide does not prolong the QT interval to any clinically relevant extent, and the LiverTox monograph records no aminotransferase or bilirubin elevations and no instances of clinically apparent liver injury. What remains genuinely open is long-term neuropsychiatric risk, growth and pubertal development in children treated from age 2, the durability of response (at least one published case lost response at 3 mg daily after eight months), and whether MC4R agonism interacts with other weight-loss pharmacology.
Legal Status
United States
Imcivree is FDA-approved (initial approval November 2020 for POMC/PCSK1/LEPR deficiency; BBS expansion June 2022; age 2–5 expansion December 2024; acquired hypothalamic obesity expansion March 19, 2026, for ages 4 and older). It is a prescription-only specialty medication. Before prescribing, the patient needs genetic testing (for POMC, PCSK1, or LEPR deficiency), a clinical diagnosis (for BBS), or a history of hypothalamic injury or dysfunction (for acquired HO). The genetic criterion is broader than most summaries suggest: the label covers variants interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS), and excludes only those classed benign or likely benign. There is no FDA-approved companion test for POMC, PCSK1, or LEPR variants, so laboratory selection and variant interpretation are left to the prescriber — payers generally will not cover the drug without documented qualifying disease. It is not a controlled substance.
International
Authorized in the EU on 16 July 2021; the EU label covers BBS and POMC/PCSK1/LEPR deficiency from age 2. After a positive CHMP opinion on 26 March 2026, the European Commission extended the authorization on 1 May 2026 to acquired hypothalamic obesity in adults and children aged 4 and above, with country launches expected from 2027. The UK MHRA added the same indication on 11 August 2026, and Japan's Ministry of Health, Labour and Welfare approved it for acquired hypothalamic obesity on 24 August 2026, with a launch expected before the end of 2026. Approval and reimbursement vary by country; rare-disease patient counts mean availability is concentrated in specialty centers under named-patient or rare-disease access programs in many jurisdictions.
Sports & Competition
Setmelanotide is not named on the WADA Prohibited List. Because it holds FDA and EU approval, it does not fall under S0, which only covers substances with no current approval by any government health authority, and off-label use does not change that. Athletes should still confirm its status with their national anti-doping organization before use.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Skin darkening from setmelanotide is permanent.
Reality
The US label calls the pigmentation effect reversible after stopping. The US label records it in 67% of treated patients versus 0% on placebo over the 14-week placebo-controlled period, and a 2026 meta-analysis of seven trials put it at 62%. It lasts through treatment and resolves after stopping; no cited source establishes how quickly it first appears. Moles can darken and new ones can appear, so skin checks before and during treatment are advised.
Myth
Setmelanotide works for anyone with an obesity-linked gene variant.
Reality
Benefit is limited to specific diagnoses. The label excludes POMC, PCSK1, or LEPR variants classed as benign or likely benign, and in the Phase 3 EMANATE trial, people carrying a single copy of a POMC/PCSK1, LEPR, SRC1, or SH2B1 variant did not lose significantly more BMI than on placebo.
Myth
Setmelanotide is a general-purpose weight-loss drug like semaglutide.
Reality
It is not. It is FDA-approved only for acquired hypothalamic obesity (ages 4 and older), Bardet-Biedl syndrome, and genetically confirmed POMC, PCSK1, or LEPR deficiency (ages 2 and older). The label states it would not be expected to work in general (polygenic) obesity. In unselected obesity, the magnitude of effect seen in monogenic populations does not replicate, and the side-effect profile is not justified.
Myth
Setmelanotide and Melanotan II are basically the same drug because they're both melanocortin agonists.
Reality
They share an MC4R-binding pharmacology but differ substantially. Setmelanotide is an FDA-approved cyclic octapeptide engineered for receptor selectivity, with a defined therapeutic window and a real safety database. Melanotan II is a research-chemical, non-approved cyclic heptapeptide with much broader receptor activity (more MC1R-driven tanning, more dose-related side effects) and no approved human indication. Conflating them obscures both the regulatory status and the pharmacological precision difference.
Myth
Skin darkening on setmelanotide means the drug is harming the patient.
Reality
Hyperpigmentation is an expected pharmacological effect from MC1R cross-activation, not a toxicity signal. It is reversible after discontinuation. The clinically important monitoring associated with pigmentary change is dermatologic surveillance for any new or changing nevi (because of the MC1R interaction with melanocyte biology), not the pigmentation itself.
Myth
If a person is obese and didn't respond to diet and lifestyle, they likely have one of the genetic mutations setmelanotide treats.
Reality
POMC, PCSK1, LEPR, and BBS-related obesity are rare, and even acquired hypothalamic obesity — which follows hypothalamic tumors, their treatment, or injury — affects only about 10,000 people in the US by Rhythm's estimate. The vast majority of severe obesity is polygenic, not monogenic. Genetic testing should be guided by clinical phenotype (very early onset, hyperphagia, syndromic features) rather than treatment-resistant obesity alone.
Myth
Setmelanotide proves MC4R agonism works for obesity in general.
Reality
The field concluded the opposite before setmelanotide existed. Merck's MC4R agonist MK-0493 produced only small, statistically insignificant weight loss versus placebo in unselected obese adults, and its investigators concluded that MC4R agonism was unlikely to be a viable antiobesity approach at all. Setmelanotide itself was studied in common obesity in at least four early trials. What changed was not the pharmacology but the population: the drug produces large effects only where the upstream signal is genuinely missing. The label states plainly that safety and effectiveness have not been established in patients without a qualifying diagnosis and that the drug is not approved to treat them.
Myth
Setmelanotide is engineered to be highly selective for MC4R, so pigmentation is a surprise.
Reality
The selectivity is real but modest, and the pigmentation is arithmetic rather than accident. The label states setmelanotide has 20-fold less activity at MC3 and MC1 receptors than at MC4 — enough to make MC4R the dominant target, nowhere near enough to spare melanocytes, which is why roughly two-thirds of patients pigment. Medicinal chemists treat it as a ceiling to be improved on: a 2026 redesign achieved over 100-fold selectivity over MC1R and MC3R and framed its own goal as fixing setmelanotide's dose-limiting off-target hyperpigmentation.
Myth
Setmelanotide is an approved treatment for Prader-Willi syndrome.
Reality
It is not, and the history is instructive. A 40-patient Phase 2 trial in Prader-Willi syndrome ran in 2015 and did not lead to an approval; Rhythm's own no-charge genetic testing programme explicitly excludes Prader-Willi syndrome from its panel. A second Phase 2 trial in Prader-Willi syndrome (ages 6 to 65) has only recently completed its 52-week course, and a separate Phase 3 trial in congenital hypothalamic obesity is recruiting. Prader-Willi hyperphagia is a reasonable hypothesis for MC4R-pathway pharmacology, not a settled indication.
Myth
Setmelanotide can be safely combined with PT-141 because they hit different melanocortin receptors.
Reality
Both activate MC4R as part of their pharmacology and have overlapping central effects (sexual arousal, blood pressure changes, nausea). Combining them has not been studied, is not an approved regimen, and increases the likelihood of pharmacodynamic adverse effects without a clear benefit rationale.
Published Research
56 studiesImpact of setmelanotide on metabolic syndrome risk in patients with proopiomelanocortin or leptin receptor deficiencies.
Acquired hypothalamic obesity as α-MSH deficiency syndrome: a paradigm shift with therapeutic impact.
Human genetic evidence challenges NCOA1 as a monogenic obesity gene.
Explains part of why the EMANATE trial failed. NCOA1, encoding SRC-1, had been proposed as a monogenic obesity gene, which is why SRC1 variant carriers were enrolled in EMANATE; this study found no association between pathogenic NCOA1 variants and either obesity or BMI.
Measuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item.
Sequential Liraglutide and Setmelanotide Therapy in Bardet-Biedl Syndrome: Metabolic and Renal Outcomes in a Real-World Case Report and Literature Review.
Setmelanotide Response Variability in Two Genetically Confirmed Pediatric Kidney Transplant Recipients with Bardet-Biedl Syndrome.
The only published interaction observation involving a narrow-therapeutic-index immunosuppressant: ciclosporin trough concentrations and graft function stayed stable across both transplant recipients, with hyperpigmentation the sole treatment-related effect. It also documents the clearest published loss of response, one patient's BMI rising from 38.0 to 42.7 by eight months despite 3 mg daily.
Setmelanotide (Drugs and Lactation Database, LactMed)
Hunger, satiety, and eating behavior after craniopharyngioma - narrative review on current management and future therapeutic perspectives.
Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.
Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders.
Melanocortin-4 Receptor Regulation of Endocrine Axes and Clinical Effects of Setmelanotide.
Quality of life improvements with setmelanotide treatment in acquired hypothalamic obesity: TRANSCEND trial interview results from US participants.
Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The TRANSCEND Phase 3 primary publication (NEJM, July 2026). In 120 participants aged 4 to 66 with acquired hypothalamic obesity, BMI changed by −16.5% on setmelanotide versus +3.3% on placebo at 52 weeks, with greater hunger reduction; serious adverse events occurred in 28% versus 8%.
Safety and effectiveness of setmelanotide in young patients with severe obesity due to craniopharyngioma: a real world monocentric experience.
Melanocortin-4 Receptor Agonist Treatment of Hypothalamic Obesity in ROHHAD Syndrome
Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency.
Setmelanotide in Bardet-Biedl Syndrome: A Case Report.
Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity
2026 Drugs review of pharmacotherapy for acquired hypothalamic obesity — the strongest peer-reviewed anchor for setmelanotide's March 2026 acquired-HO approval now complemented by the primary TRANSCEND publication (NEJM, July 2026).
SAR investigation and synergistic optimization of setmelanotide yields a potent, selective, and soluble MC4R agonist
Case Report: Improvement in cognitive functioning following setmelanotide initiation in a patient with Bardet-Biedl syndrome
Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis.
The first pooled quantification of setmelanotide's safety profile. Meta-analysis of seven trials (n=185) found injection-site reactions in 96%, skin hyperpigmentation in 62%, nausea in 36%, vomiting in 26% and diarrhoea in 21%; a parallel disproportionality analysis of 228 FAERS reports flagged hyperpigmentation, injection-site reactions, nausea, melanocytic naevi and freckling as the key signals.
Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome
Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial
The VENTURE trial in 12 children aged 2 to 5 with POMC, LEPR, or BBS-related obesity: 10 of 12 reached at least a 0.2-point BMI Z-score reduction at 52 weeks, with a mean BMI change of −18% — the basis of the December 2024 expansion to age 2.
Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction
Clinically Meaningful Outcomes after 1 Year of Treatment with Setmelanotide in an Adult Patient with a Variant in SH2B1
Setmelanotide
The NIDDK LiverTox entry, not a journal review. Cited because of what it rules out: setmelanotide has not been associated with serum aminotransferase or bilirubin elevations, or with any instance of clinically apparent liver injury.
Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial
Open-label Phase 2 trial in 18 patients with acquired hypothalamic obesity: 16 of 18 met the primary endpoint of at least 5% BMI reduction at 16 weeks, with a mean BMI reduction of 15% — the signal that led to the TRANSCEND Phase 3 trial.
Could setmelanotide be the game-changer for acquired hypothalamic obesity?
Beneficial Effects of Setmelanotide in a 5-Year-Old Boy With POMC Deficiency and on His Caregivers
Efficacy and Safety of Setmelanotide, a Melanocortin-4 Receptor Agonist, for Obese Patients: A Systematic Review and Meta-Analysis
Setmelanotide (StatPearls)
Setmelanotide: a promising advancement for pediatric patients with rare forms of genetic obesity
Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period
The randomized Phase 3 trial in Bardet-Biedl and Alström syndromes (Lancet Diabetes Endocrinol 2022): 32.3% of patients aged 12 and older with BBS reached at least 10% weight loss after 52 weeks, supporting the 2022 BBS approval; skin hyperpigmentation occurred in 61%.
Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity
Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency
Setmelanotide (Imcivree) for rare genetic forms of obesity
Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway
Setmelanotide: First Approval
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
The pivotal single-arm Phase 3 trials in POMC/PCSK1 and LEPR deficiency (Lancet Diabetes Endocrinol 2020). At about one year, 8 of 10 POMC and 5 of 11 LEPR participants lost at least 10% of body weight, with a blinded placebo-withdrawal period confirming the effect — the basis of the 2020 FDA approval.
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency
Nature Medicine 2018 report extending the approach to leptin receptor deficiency: three severely obese LEPR-deficient patients given setmelanotide had sustained weight loss and reduced hunger, supporting the LEPR arm of the later Phase 3 program.
Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
The first-in-patient report (NEJM 2016): two patients with POMC deficiency treated with setmelanotide lost substantial weight and reported reduced hunger, establishing proof of concept for MC4R-pathway replacement in monogenic obesity.
RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals
Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.
The primate study that made setmelanotide developable. BIM-22493 (RM-493, the setmelanotide precursor) produced a transient 35% drop in food intake but persistent 13.5% weight loss over 8 weeks with no rise in blood pressure or heart rate, while LY2112688 — an earlier MC4R agonist known to raise blood pressure in humans — did exactly that in the same model while only modestly reducing intake.
Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy.
The trial that nearly closed the field. Merck's MK-0493 produced only small, statistically insignificant weight loss versus placebo at 12 weeks in unselected obese adults, and the authors concluded that MC4R agonism was unlikely to be a viable antiobesity approach. Setmelanotide's answer was not a better agonist but a different population — patients whose upstream signalling is actually broken.
Rhythm Pharmaceuticals: EMANATE Phase 3 results in heterozygous variant carriers (March 16, 2026, SEC Form 8-K exhibit)
Rhythm Pharmaceuticals: MHLW approval of IMCIVREE for acquired hypothalamic obesity in Japan (August 24, 2026)
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
FDA Approves Expanded Indication for Imcivree as Treatment for Hypothalamic Obesity (PharmExec)
NCT06760546 — Phase 3 study of setmelanotide in congenital hypothalamic obesity (recruiting)
NCT06772597 — Phase 2 study of setmelanotide in Prader-Willi syndrome, ages 6 to 65, 52 weeks
NCT05046132 — Phase 4 thorough-QT study of setmelanotide in healthy volunteers (n=77, completed)
Quick Facts
- Class
- Melanocortin-4 Receptor Agonist
- Tier
- B
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Nov 2026
- Citations
- 56PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.